check box
morn provid financi updat ahead industri confer
see sever posit affirm convict thesi first holog
deliv quarterli revenu million better forecast guidanc
midpoint million result balanc across busi
segment compani note better perform breast health molecular
diagnost intern result impli deliv organ growth
adjust sell day view strong result second cynosur
stabil deliv in-lin revenu million believ help show
bottom salesforc contribut new product help
achiev double-digit growth third compani highlight
major beneficiari tax reform new effect rate
vs prior guidanc continu view valuat compel
context solid result busi fundament reiter
overweight rate price target repres ebitda
also repres ep sept year end
observ busi perform solid estim
organ growth adjust sell day total growth constant currenc
estim ad sell day chang headwind
segment breast health drove notabl beat vs expect gyn
surgic miss forecast manag note press releas result
driven strength breast health molecular diagnost intern
busi note sell day impact greater impact busi high
recur revenu exposur diagnost gyn surgic well servic
revenu growth quarter note expect major benefit us tax
reform new effect tax rate approxim vs prior guidanc
given disclosur rais ep estim
ep estim
quarterli annual ep usd
consensu number thomson reuter
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
return equiti ttm
link barclay live interact chart
margin return data
balanc sheet cash flow
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight believ grow
stronger longer driven longer
mammographi tail mdx growth panther
myosur tuck-in new product launch
could drive modest upsid revenu
mdx gyn surgic busi continu
drive outsiz growth new product launch
add modestli growth upsid case
reflect upsid earn power
penetr rate us mammographi
busi slow faster expect downsid
case reflect downsid earn
power
morn provid financi updat ahead industri confer
see sever posit affirm convict thesi first holog
deliv quarterli revenu million better forecast guidanc
midpoint million result balanc across busi
segment compani note better perform breast health molecular
diagnost intern result impli compani deliv organ growth
adjust sell day view strong result second cynosur
stabil deliv in-lin revenu million believ help show
bottom salesforc contribut new product help
compani achiev double-digit growth third compani highlight
major beneficiari tax reform new effect rate
vs prior guidanc continu view valuat compel context
solid result busi fundament reiter overweight rate
price target repres ebitda also repres
ep sept year end
busi perform solid estim organ growth
adjust sell day post million revenu
upper end prior revenu rang million well forecast
million repres total growth y/i compani note
constant currenc given disclosur blood screen contribut million
cynosur ad million y/i impli organ growth quarter
estim sell day headwind given fewer day y/i
impact recur sale period ad back sell day impact
adjust organ growth quarter
look result segment breast health drove notabl beat vs
expect gyn surgic miss forecast manag note press
releas result driven strength breast health molecular diagnost
intern busi note sell day impact greater impact
busi high recur revenu exposur diagnost gyn surgic
well servic revenu growth quarter
note expect major benefit us tax reform compani
new effect tax rate approxim vs prior guidanc
huge surpris us screen one biggest beneficiari
tax reform coverag sale gener domest new tax rate
take effect start compani view level good run-
rate move forward note effect tax rate neg
year base revalu defer tax given disclosur rais
ep estim ep estim
meehan cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
author contribut research report research analyst unless otherwis indic
public date top report reflect local time report produc may differ releas date provid
gmt
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
http //publicresearch barcap com/static/ researchdissemin html order access barclay research conflict manag polici
statement pleas refer http //publicresearch barcap com/static/ conflictmanag html
procedur pleas
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis barclay research depart
oper independ absa research depart absa research produc absa bank limit act corpor
invest bank divis part barclay africa group limit affili invest bank barclay bank plc elig
client may receiv research report research depart may reach differ conclus may contain differ
conflict forecast recommend trade idea
price sourc thomson reuter last avail close price relev trade market
